https://scholars.lib.ntu.edu.tw/handle/123456789/369402
標題: | The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats | 作者: | Hsu, S.-J. Hsin, I.-F. Lin, Y.-L. YI-CHEN CHEN Huang, H.-C. Lee, F.-Y. Lin, H.-C. Chang, C.-C. Lee, S.-D. |
關鍵字: | Hepatic encephalopathy; Liver cirrhosis; Oxidative stress; Portal hypertension; Sorafenib | 公開日期: | 2012 | 卷: | 42 | 期: | 12 | 起(迄)頁: | 1309-1316 | 來源出版物: | European Journal of Clinical Investigation | 摘要: | Background Sorafenib, a multikinase inhibitor that inhibits angiogenesis and carcinogenesis, has been used for patients with advanced hepatocellular carcinoma. However, sporadic cases have been reported with the development of hepatic encephalopathy (HE) after sorafenib treatment, mostly in those with cirrhosis. Liver function impairment, portal-systemic collaterals and brain oxidative stress participate in the pathogenesis of HE. The study therefore aimed to investigate the potential influences of sorafenib on HE and the relevant risk factors in cirrhotic rats. Methods Liver cirrhosis was induced in Spraque-Dawley rats with common bile duct ligation (CBDL). CBDL rats received sorafenib 1mg/kg/day or distilled water (DW) via oral gavage since the 15th day post surgery for 2weeks. On the 28th day, after motor activities measurements, mean arterial pressure, portal pressure and heart rate were checked. Thereafter, cerebral cortex and cerebellum were dissected for oxidative stress study and blood was collected for liver biochemistry survey. Results Sorafenib significantly reduced portal pressure (22%) and collateral shunting degree (15%) in cirrhotic rats. Alanine transaminase, aspartate transaminase, total bilirubin and ammonia were similar in sorafenib- and DW-treated groups. Motor activities were not significantly altered by sorafenib. In cerebrum, the oxidant and antioxidant substances activities were not significantly different between the two groups, whereas they were divergent in cerebellum and hippocampus. Conclusion By surveying three main aspects involved in the pathogenesis of HE, this study demonstrates that sorafenib does not increase the risk of HE in cirrhotic rats. ? 2012 Stichting European Society for Clinical Investigation Journal Foundation. |
URI: | http://www.scopus.com/inward/record.url?eid=2-s2.0-84869869780&partnerID=MN8TOARS http://scholars.lib.ntu.edu.tw/handle/123456789/369402 |
DOI: | 10.1111/eci.12006 | SDG/關鍵字: | alanine aminotransferase; ammonia; aspartate aminotransferase; bilirubin; glutathione; malonaldehyde; sorafenib; superoxide dismutase; animal experiment; animal model; animal tissue; antioxidant activity; article; bile duct ligation; body weight; brain cortex; brain tissue; cerebellum; controlled study; heart rate; hemodynamics; hepatic encephalopathy; histopathology; liver cirrhosis; male; mean arterial pressure; motor activity; nonhuman; oxidative stress; portal vein blood pressure; priority journal; rat; risk factor; Animals; Disease Models, Animal; Hepatic Encephalopathy; Humans; Hypertension, Portal; Liver Cirrhosis, Experimental; Male; Niacinamide; Oxidative Stress; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley |
顯示於: | 動物科學技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。